Back
Beam Therapeutics Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
52
BEAM
Beam Therapeutics
Last Price:
24.62
Seasonality Move:
42.3%
7 Day Trial
ALL ACCESS PASS
$
7
Access The Stock Grader Trading Tool From "The King Of Quants"
More details here...Beam Therapeutics Price Quote
$24.62
+1.04 (+4.41%)
(Updated: November 22, 2024 at 1:20 PM ET)
Beam Therapeutics Key Stats
Buy
52
Beam Therapeutics (BEAM)
is a Buy
Day range:
$23.33 - $24.71
52-week range:
$20.84 - $49.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.52
P/B ratio:
2.47%
Volume:
1M
Avg. volume:
1.3M
1-year change:
-15.64%
Market cap:
$2B
Revenue:
$377.7M
EPS:
$-1.76
How Much Does Beam Therapeutics Make?
-
How Much Are Beam Therapeutics's Sales Annually?
BEAM Revenues are $377.7M -
How Much Profit Does Beam Therapeutics's Make A Year?
BEAM net income is -$132.5M
Is Beam Therapeutics Growing As A Company?
-
What Is Beam Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.17% -
What Is Beam Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Beam Therapeutics Stock Price Performance
-
Did Beam Therapeutics Stock Go Up Last Month?
Beam Therapeutics share price went up by 1.86% last month -
Did BEAM's Share Price Rise Over The Last Year?
BEAM share price fell by -15.64% over the past 1 year
What Is Beam Therapeutics 52-Week High & Low?
-
What Is Beam Therapeutics’s 52-Week High Share Price?
Beam Therapeutics has traded as high as $49.50 over the past 52 weeks -
What Is Beam Therapeutics’s 52-Week Low Share Price?
Beam Therapeutics has traded as low as $20.84 over the past 52 weeks
Beam Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Beam Therapeutics?
-
How Much Debt Does Beam Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Beam Therapeutics Have?
Cash and short term investments quarterly total is $925.8M -
What Is Beam Therapeutics’s Book Value Per Share?
Book value per share is 9.58
Is Beam Therapeutics Cash Flow Positive?
-
What Is BEAM Cash Flow From Operations?
Cash flow from operations (TTM) is -$135.8M -
What Is Beam Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $38M -
What Is Beam Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $156.8M
Beam Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
BEAM return on invested capital is -16.62% -
What Is Beam Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -10.97% -
What Is BEAM Return On Equity?
ROE is a measure of profitability and is -16.62%
Beam Therapeutics Earnings Date & Stock Price
-
What Is Beam Therapeutics's Stock Price Today?
A single share of BEAM can be purchased today for 23.58 -
What Is Beam Therapeutics’s Stock Symbol?
Beam Therapeutics trades on the nasdaq under the ticker symbol: BEAM -
When Is Beam Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Beam Therapeutics is scheduled on February 27, 2025 -
When Is BEAM's next ex-dividend date?
Beam Therapeutics's next ex-dividend date is May 7, 2020 -
How To Buy Beam Therapeutics Stock?
You can buy Beam Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Beam Therapeutics Competitors
-
Who Are Beam Therapeutics's Competitors?
Below is a list of companies who compete with Beam Therapeutics or are related in some way:
Beam Therapeutics Dividend Yield
-
What Is BEAM Dividend Yield?
Beam Therapeutics’s dividend yield currently is 0% -
What Is Beam Therapeutics’s Payout Ratio?
Beam Therapeutics’s payout ratio is 0% -
When Did Beam Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 22, 2024 -
What Is Beam Therapeutics’s Dividend Per Share?
Beam Therapeutics pays a dividend of $0.00 per share
Beam Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 0.93% |
| Revenue: | -17.01% | 0.97% |
Analyst Recommendations
| Buy Recommendations: | 7 |
|---|---|
| Hold Recommendations: | 8 |
| Sell Recommendations: | 0 |
| Price Target: | 49.20 |
| Upside from Last Price: | 108.65% |